|
| Mouse model | Age | Test | Behavioural outcome | Increased neurogenesis by | Ref |
|
| APP/PS1 | 8 months | MWM | ↑ escape latency, ↓ time in target quadrant, ↓ platform crossings | b2AR activation (clenbuterol) | 46 |
| 8-9 months | PA (a) | ↓ latency and ↑ frequency to enter in dark compartment | osthole (a), (b) | 51 |
| MWM (b) | ↑ escape latency, ↑ distance from platform, ↓ platform crossings |
| 6 months | MWM | ↑ escape latency | L-3-n-butylphthalide (L-NBP) | 52 |
| 12 months | MWM (a) | ↑ escape latency, ↓platform area crossings, ↓ time spent in target quadrant | NSC translpant (a), (b) | 75 |
| SD (b) | ↓ latencies; ↑ error time |
| 1,3,6,9,12 months | FC | ↓ freezing from 6 months of age | social interaction | 76 |
| 2 months | EPM (a) | = time and number of entries in open arms | enriched environment (a) | 87 |
| FC (b) | = time in freezing | - |
| 6 months | NOR (a) | ↓ recognition index | PDE7 inhibitor (S14) (a), (b) | 77 |
| MWM (b) | ↑ escape latency |
| 12 months | MWM | ↑ escape latency, ↓ time in target quadrant, ↓ platform area crossings | running | 78 |
| 9 months | MWM | ↑ escape latency, ↓ platform area crossings, ↓ time in target quadrant | osthole | 81 |
| 8 months | MWM | ↑ escape latency, ↓ time in target quadrant | MDA7 (CB2 receptors agonist) | 83 |
| 4, 7-8 months | MWM (radial version) | ↑ error rate | FGF2 | 107 |
| 18 weeks | NOR (a) | ↓ recognition index | minocycline (a) | 109 |
| YM (b) | = alternation rate |
| 7 months | MWM (radial version) | ↑ error rate | IL-10 | 113 |
|
| APP/PS1ΔΕ9 | 28 weeks (female) | MWM | ↑ escape latency, ↓ time in platform area, ↓ platform crossings | metformin | 44 |
| 3 months | nest building behavior (a) | ↓ nesting score | yonkenafil (a, dose-dependent), (b), (c, dose-dependent) | 57 |
| SA (b) | ↓ alternation and arm entries |
| MWM (c) | ↓ escape latency, ↓ platform crossings |
| 9-18 months | SA | ↓ alternation rate at 18 months age | Paroxetine | 72 |
| 3 months | OF (a) | = locomotor activity | xanthoceraside (b, dose-dependent), (c, dose-dependent) | 73 |
| YM (b) | ↓ spontaneous alternation |
| NOR (c) | ↓ discrimination index |
| 3, 9 months | NOR | = exploration for novel object at 3 months | - | 80 |
| Locomotor activity | ↑ activity at 3 months | - |
| YM | = time in open arms at 3 months | - |
| MWM | ↑ escape latency at 9 months | - |
| 9 months | MWM | ↑ escape latency, ↓ platform area crossings and time in target quadrant | osthole | 82 |
| 8-9 months (female) | OL | ↓ exploratory preference for displaced object | enhancing functional integration of new neurons | 85 |
|
| APP/PS1 KI | 6 months | EPM (a) | ↑ time in open arms | - | 71 |
| YM (b) | ↓ alternation rate | - |
| 2-6 months | neurological evaluation (a) | ↓ of vertical activity (age-related), = other parameters, hyperactivity | - | 79 |
| 6 months | EPM (b) | ↑ time in open arms | - |
| 2, 4, 6 months | MWM (c) | ↓ in goal target (age-related), ↓ accuracy (age-related) | - |
|
| APPSw,Ind | 4 months (plus 7 weeks EE) | MWM | ↑ escape latency, ↓ time in platform area, ↓platform crossings | Environmental Enrichment | 50 |
|
| Tg2576 | 3,6, 9 months | FC (contextual and cue) | ↓ freezing to context after stress (isolation) at 6 and 9 months | Fluoxetine | 43 |
|
| 3xTgAD | 6 months | OL | ↓ exploratory preference for displaced object | THIP (Gaboxadol) | 68 |
| FC (pattern separation) | ↑ trials for discrimination |
| 3 months | TEC | ↓ conditioned responses | Allopregnanolone | 48 |
|
| CRND8 | 3, 7 months | SD (a) | ↓step-down latency | Lithium salts (a) 3 months only, (b) 3 months only | 74 |
| MWM (b) | ↑ escape latency, ↓ time in target quadrant |
|
| ApoE3-Ki and ApoE-4 KI | 10-17 months | MWM (a) | ↓ ApoE4-KI preference for target quadrant (respect to Apoe3-KI) | Transplant of embryonic interneuron progenitor (a), (b), (c) | 119 |
| OF (b) | ↓ ApoE4-KI time in central area (respect to Apoe3-KI) |
| EPM (c) | ↓ ApoE4-KI time in open arms (respect to Apoe3-KI) |
|
